...
首页> 外文期刊>Cardio-oncology. >A case of irreversible bradycardia after rituximab therapy for diffuse large B-cell lymphoma
【24h】

A case of irreversible bradycardia after rituximab therapy for diffuse large B-cell lymphoma

机译:用于弥漫性大B细胞淋巴瘤的Rituximab疗法后不可逆的心动过缓的情况

获取原文
           

摘要

This is a case of a middle-aged woman with underlying cardiac conduction system with episodes of AV Wenckebach, who subsequently developed significant AV conduction system abnormalities after receiving one standard dose of Rituximab infusion for diffuse large B-cell lymphoma. Rituximab, being a monoclonal antibody against CD-20 antigen, is effective in treatment of B-cell lymphoma but may also cause bradyarrythmias likely due to the calcium ion channel property of CD-20 antigen.
机译:这是一个带有底层心脏传导系统的中年女性的案例,其具有AV Wenckebach的剧集,其随后在接受一个标准剂量的Rituximab输注后显着的AV传导系统异常,用于弥漫性大B细胞淋巴瘤。 Rituximab是针对CD-20抗原的单克隆抗体,可有效地治疗B细胞淋巴瘤,但也可能由于CD-20抗原的钙离子通道特性而导致可能的Bradyarrythmias。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号